International Journal of Nanomedicine · 2013 · 25 citations · 28 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DeliveryNanoparticle Drug DeliveryCancer NanomedicineCancer Stem CellsCell-nanoparticle InteractionsMultiple MyelomaNanocarriers For TherapeuticsNanomedicineAnticancer ActivityCancer NanotherapyCancer Stem-like CellsIron Oxide NanoparticlesMultifunctional NanoparticlesMultiple Myeloma TherapyMultiple Myeloma TreatmentNanoparticles
BACKGROUND: There is growing evidence that CD138(-) CD34(-) cells may actually be tumor stem cells responsible for initiation and relapse of multiple myeloma. However, effective drugs targeted at CD138(-) CD34(-) tumor stem cells are yet to be developed. The purpose of this study was to investigate the inhibitory effect of paclitaxel-loaded Fe3O4 nanoparticles (PTX-NPs) on CD138(-) CD34(-) tumor stem cells in multiple myeloma-bearing mice. METHODS: CD138(-) CD34(-) cells were isolated from a human U266 multiple myeloma cell line using an immune magnetic bead sorting method and then subcutaneously injected into mice with nonobese diabetic/severe combined immunodeficiency to develop a multiple myeloma-bearing mouse model. The mice were treated with Fe3O4 nanoparticles 2 mg/kg, paclitaxel 4.8 mg/kg, and PTX-NPs 0.64 mg/kg for 2 weeks. Tumor growth, pathological changes, serum and urinary interleukin-6 levels, and molecular expression of caspase-3, caspase-8, and caspase-9 were evaluated. RESULTS: CD138(-) CD34(-) cells were found to have tumor stem cell characteristics. All the mice developed tumors in 40 days after injection of 1 × 10(6) CD138(-) CD34(-) tumor stem cells. Tumor growth in mice treated with PTX-NPs was significantly inhibited compared with the controls (P < 0.005), and the groups that received nanoparticles alone (P < 0.005) or paclitaxel alone (P < 0.05). In addition, the PTX-NPs markedly inhibited interleukin-6 secretion, increased caspase-8, caspase-9, and caspase-3 expression, and induced apoptosis of tumor cells in the treated mice. CONCLUSION: PTX-NPs proved to be a potent anticancer treatment strategy that may contribute to targeted therapy for multiple myeloma tumor stem cells in future clinical trials.
28
Characterization of clonogenic multiple myeloma cells
William Matsui, Carol Ann Huff, Qiuju Wang et al. · Blood · 2003 · 792 citations · Full text
Medicine, Cell Biology, Oncology +12
Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Si‐Shen Feng, Mu Li, Khin Yin Win et al. · Current Medicinal Chemistry · 2004 · 309 citations
Pharmacy, Oncology, Pharmacology +17
Diana Cirstea, Teru Hideshima, Scott J. Rodig et al. · Molecular Cancer Therapeutics · 2010 · 166 citations · Full text
Medicine, Oncology, Pharmacology +14